Additionally, novel second-generation ALK inhibitors, such as lorlatinib (PF06463922), ceritinib (LDK378), and ensartinib, that are effective against the crizotinib-resistant ALKF1174L mutant [58,59] are currently being evaluated in clinical trials for children with neuroblastoma (NCT01742286, NCT03107988, NCT03213652), with early results showing responses to ceritinib in six of nine patients with anaplastic large cell lymphoma (ALCL) and myofibroblastic tumors with ALK gene aberrations. Here, ALK is linked to neuroblastoma.